Radiodermatitis or radiation dermatitis is a condition caused by radiation therapy that is used for cancer treatment. This condition is caused by the high-energy waves or particles, namely x-rays, gamma rays, protons, or electron beams which are delivered during the radiation therapy. Radiodermatitis occurs in nearly 95% of the patients receiving radiation therapy, especially patients with head & neck cancer, breast cancer, skin cancer, sarcoma, or lung cancer. Radiodermatitis may be chronic or acute and includes localized erythema, hair loss (epilation), skin peeling (desquamation), necrosis, fibrosis, and other related conditions. The condition is usually treated with topical agents like topical antibiotics, corticosteroids, hydrophilic creams; oral medications such as oral analgesics, oral corticosteroids, antibiotics, and anti-inflammatory agents; and dressings.
COVID-19 Impact on Radiodermatitis Market
The outbreak of COVID-19 across the globe has adversely affected the global radiodermatitis market growth. Many manufacturers namely Convatec Group Plc and BMG Pharma SPA operating in the radiodermatitis market faced challenges in supply of their products due to lockdown restrictions imposed by various governments across the globe to curb the spread of the coronavirus. Besides, multiple hospitals around the globe decreased the radiotherapy treatment and focused on supporting the COVID-19 departments.
However, the leading cancer institutions such as the Italian Association of Radiotherapy & Clinical Oncology (AIRO), in June 2020 reported that radiotherapy has proven to be the most appropriate and the safest cancer treatment, throughout the COVID-19 outbreak. Radiodermatitis is a common side-effect of radiotherapy that can cause the damage to skin cells of the patient. Thus, the demand for radiodermatitis products may rise and progressively impact the global market, after the COVID-19 crisis.
Radiodermatitis Market Trends and Developments
The companies operating in the global industry are adopting several growth strategies and business tactics such as partnerships, collaboration, business expansion, and product launches to obtain a leading position in the global industry, which is predicted to drive the global radiodermatitis market growth in the upcoming years.
For instance, in April 2019, CIVCO Radiotherapy, the leading provider of innovative, high quality, patient-centric radiotherapy solutions, collaborated with Stratpharma AG, a Swiss company specializing in innovative topical medical products, to expand and focus on wound care in radiation therapy patients. The aim of both the companies is to focus on patient outcomes in the radiation therapy space.
In July 2020, AMERI Holdings, Inc., the US based IT service management company, announced that its proposed amalgamation partner, Jay Pharma Inc., an authorized distributor for some of the leading Indian & Multinational Pharmaceutical companies, may file 2 new investigational new drug (IND) applications for the treatment of radiodermatitis and glioblastoma multiforme (GBM).
In July 2020, KeraNetics Inc., the global leader in the manufacturing & development of purified keratin medical products, announced the addition of ‘KeraStat Cream’ to its KeraStat wound dressing portfolio. The KeraStat Cream has received the US Food & Drug Administration (FDA) approval for indications of radiation dermatitis. This product is especially designed by the company to reduce the skin damage and painful ulceration that occurs during the radiation therapy.
Forecast Analysis of Global Market
The global radiodermatitis market is projected to witness an exponential growth during the forecast period, owing to the rapid expansion of healthcare establishments in the Asian countries such as India, China, Japan, and Singapore in the recent several years. Conversely, the lack of awareness regarding the acute and chronic radiodermatitis across the pharmacies in the low- and middle- income countries is expected to hamper the market growth in the projected timeframe.
The growing prevalence of cancer along with the rising adoption of radiotherapy across the globe are the significant factors and radiodermatitis market trends estimated to bolster the growth of the global market in the coming future. According to a latest report published by Research Dive, the global radiodermatitis market is expected to garner $561.7 million during the forecast period (2021-2028). Regionally, the North America region is estimated to observe the fastest growth by 2028, owing to the presence of leading market players and the rising incidence of cancer-causing diseases in the region. The key players functioning in the global market include 3M Company, HARTMANN, Mölnlycke, KeraNetics, Inc., Charles River Laboratories, Smith & Nephew Plc., The Jackson Laboratory, InterMed S.A, Stratpharma, and AceTech.